This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Q4 Earnings Beat, Operating Margin Rises
by Zacks Equity Research
Excluding the Diabetes group, Medtronic (MDT) displays better performances at CER on the back of growth in rest of the business segments and across all geographies.
Here's Why You Should Hold On to Integra LifeSciences Stock
by Zacks Equity Research
Investor confidence is still high on growth prospects of Integra LifeSciences (IART).
QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access
by Zacks Equity Research
This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.
Hologic Breast Health Arm Aids Strongly, Rising Costs Ail
by Zacks Equity Research
Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.
Will RTG Again Bolster Medtronic's (MDT) Earnings in Q4?
by Zacks Equity Research
Within Neurovascular, we hope to witness strength across Medtronic's (MDT) stroke franchise with growth in stent retrievers, flow diverters, neuro access and embolic products.
ResMed Study Shows Remote Monitoring Benefits on CPAP Use
by Zacks Equity Research
Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) benefits from launches like Halo ION.
Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring
by Zacks Equity Research
Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.
Avedro (AVDR) Hits a 52-Week High on Solid Growth Prospects
by Zacks Equity Research
Avedro (AVDR) gains from promising developments in recent times.
Varian Medical's CTSI Buyout to Boost Oncology Services Unit
by Zacks Equity Research
The CTSI buyout is expected to prove accretive to Varian Medical's (VAR) adjusted earnings per share during fiscal 2021.
Why Should You Hold on to Myriad Genetics (MYGN) Stock?
by Zacks Equity Research
Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).
LabCorp Grows on Strong Diagnostics Arm Amid Contract Losses
by Zacks Equity Research
LabCorp's (LH) diagnostics business grows organically despite additional price reductions.
Medtronic (MDT) Launches Telescope Guide Extension Catheter
by Zacks Equity Research
The launch of Telescope marks Medtronic's (MDT) foray into the guide extension catheter market.
ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI
by Zacks Equity Research
ABIOMED's (ABMD) Impella CP receives Japanese PMDA approval in recent times.
QIAGEN Partners Inovio to Develop Companion Diagnostics
by Zacks Equity Research
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site
by Zacks Equity Research
The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.
Here's Why You Should Hold on to Tandem (TNDM) Stock for Now
by Zacks Equity Research
Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.
Varian Medical Installs ProBeam at Research Hub in Singapore
by Zacks Equity Research
Varian Medical's (VAR) APAC revenues grow 7% year over year in the fiscal second quarter.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
ResMed (RMD) continues to see strong sales from SaaS business as well as new mask products and devices.
STERIS (STE) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the reported quarter.
ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals
by Zacks Equity Research
ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients.
Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid
by Zacks Equity Research
Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.
Masimo (MASI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 5.33% and 3.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Masimo Gets CE Mark for ANI Module, Enhances Root Platform
by Zacks Equity Research
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.
Masimo (MASI) Reports Next Week: What Awaits?
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.